XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOANS PAYABLE
6 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
LOANS PAYABLE

NOTE 7. LOANS PAYABLE

 

On April 2, 2022, the Company and Elite Labs entered into a Loan and Security Agreement (the “EWB Loan Agreement”) with East West Bank (“EWB”). Pursuant to the EWB Loan Agreement, the Company and Elite Labs received one term loan for a principal amount of $12,000,000 (the “EWB Term Loan”) and a revolving line of credit up to $2,000,000 (the “EWB Revolver,” together with the “EWB Term Loan,” the EWB Loans”), each of which shall be used for working capital. The EWB Term Loan bears interest at a rate of 7.98% (1.73% plus the prime rate (“Prime”)) and is repayable over five years, maturing on May 1, 2027. The EWB Revolver bears interest at a rate of (7.12% (0.87% plus Prime)) and matures on May 1, 2027. The total transaction costs associated with the EWB Loans incurred as of September 30, 2022, were $40,120, which are being amortized on a monthly basis over five years, beginning in April 2022. The EWB Loans are secured by a security interest in the personal property of the Company and Elite Labs. The EWB Loan Agreement contains customary representations, warranties and covenants. These covenants include, but are not limited to, maintaining maximum leverage ratios of 3.50 to 1.00, minimum liquidity of $5,000,000, minimum cash of $1,000,000, a fixed charge coverage ratio of 1.25 to 1.00 and restrictions on mergers or sales of assets and debt borrowings. As of September 30, 2022, the Company is in compliance with each financial covenant and the Company has not used any of the Revolving line of credit.

 

On July 1, 2022, the EWB provided a mortgage loan (“EWB Mortgage Loan”) in the amount of $2.55 million for the purchase of the property at 135-137 Ludlow Avenue, which was formerly a lease held by the Company. The EWB Mortgage Loan matures in 10 years and bears interest at a rate of 4.75% fixed for 5 years then adjustable at WSJP plus 0.5% with floor rate of 4.5%. The total transaction costs associated with the EWB Mortgage Loan incurred as of September 30, 2022, were $34,952, which are being amortized on a monthly basis over ten years, beginning in July 2022. The EWB Mortgage Loan contains customary representations, warranties and covenants. These covenants include maintaining a minimum debt coverage ratio of 1.50 to 1.00 tested annually and a minimum trailing 12-month debt coverage ratio of 1.50 to 1.00. As of September 30, 2022, the Company was in compliance with each financial covenant.

 

Loans payable consisted of the following:

 

   September 30, 2022   March 31, 2022 
Equipment and insurance financing and mortgage loans payable, between 3.30% and 12.02% interest and maturing between October 2022 and June 2032  $14,902,241   $502,052 
Less: Current portion of loans payable   (391,779)   (253,006)
Long-term portion of loans payable  $14,510,462   $249,046 

 

The interest expense associated with the loans payable was $83,686 and $17,001 for the three months ended September 30, 2022 and 2021, respectively, and $261,265 and $35,598 for the six months ended September 30, 2022 and 2021, respectively.

 

 

ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

Loan principal payments for the next five years are as follows:

 

     
Years ending March 31,  Amount 
2023 (excluding the six months ended September 30, 2022)  $209,266 
2024   327,317 
2025   294,157 
2026   227,306 
2027   198,040 
2028 and thereafter   13,646,155 
Total remaining principal balance  $14,902,241